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AbsTrAcT
Most cases of pulmonary arteriovenous malformations 
occur in patients with hereditary hemorrhagic telangiec-
tasia. It is a rare disease that may present with stroke- 
like symptoms in young patients. With the development 
of occlusion devices, percutaneous embolization has 
become the treatment of choice. We report a case of 
a 33 year-old man with a history of multiple strokes, 
cyanosis, dyspnea, recurrent epistaxis and high flow 
pulmonary fistulae who was submitted to percutaneous 
embolization. The patient improved clinically and has 
had no recurring symptoms in the 30-month follow-up.
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rEsUMO
Embolização Percutânea de Fístulas Arteriovenosas 
Pulmonares em Paciente com Telangiectasia 
Hemorrágica Hereditária
A maioria dos casos de malformações arteriovenosas pulmonares 
ocorre em pacientes portadores de telangiectasia hemorrágica 
hereditária. É uma doença incomum, que pode se apresentar 
com acidentes vasculares encefálicos em pacientes jovens. 
Com o surgimento de dispositivos de oclusão, a embolização 
percutânea tornou se o tratamento de escolha. Relatamos o 
caso de um paciente de 33 anos de idade, com história de 
múltiplos acidentes vasculares encefá licos, cianose, dispneia, 
epistaxes recorrentes e presença de fístulas pulmonares de 
alto fluxo, submetido a embolização por via percutânea. 
O paciente apresentou melhora clínica, encontrando se em 
acompanhamento há 30 meses, sem sin tomas recorrentes.
DEscrITOrEs: Embolização terapêutica. Fístula arteriovenosa. 
Telangiectasia. Malformações arteriovenosas. Artéria pulmonar.
Case Report
H ereditary hemorrhagic telangiectasia, also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disorder described in the 19th century. 
It is classically diagnosed by the association of the four 
Curaçao criteria: recurrent epistaxis, multiple telangiec-
tasias in characteristic sites (lips, oral cavity, fingers, and 
nose), visceral arteriovenous malformations, and family 
history.1 There are two main types related to mutations 
of genes involved in the signalling of the transforming 
growth factor-beta (TGF-b) superfamily.2 Patients with 
hereditary haemorrhagic telangiectasia type 1 (endoglin) 
have epistaxis in 50% of cases at approximately the 
age of 10 years, and higher frequency of symptoma-
tic pulmonary arteriovenous malformations and brain 
abscesses,3 while patients with hereditary haemorrhagic 
telangiectasia type 2 (ACVRL1) have epistaxis ten years 
later than type 1, and only this type has symptomatic 
hepatic involvement.
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an adductor artery of 3.5 mm in diameter), and patent 
foramen ovale (Figure 1). There was no hypertension 
in left and right chambers, arterial saturation was low 
(84.2%), and the calculated flow through the fistula was 
0.89 L/min, with a flow ratio Qp/Qs of 0.83.
Percutaneous treatment was chosen, which was per-
formed under local anaesthesia and mild sedation (Figures 
2 A, B, and C). The patent foramen ovale was occluded 
using a 25-mm IntraseptTM prosthesis (Cardia – Burnsville, 
United States) without complications. After that, adductor 
artery embolisation of the large pulmonary arteriovenous 
fistula was performed using 10-mm and 16-mm diameter 
AmplatzerTM Vascular Plug prostheses (St. Jude Medical 
– St. Paul, United States). Despite the proper positioning 
of the plugs, significant residual flow was observed, and 
a reassessment after a few days was scheduled.
In a new study performed after five days, only 
partial thrombosis of the vascular plugs was observed, 
as well as persistence of high flow through the fistula. 
A new embolisation was performed using two MWCE-
35-14-10-Nester coils, one MWCE-35-14-8-Nester coil, 
three MWCE-35-8-4-Tornado coils, and two MWCE-
35-8-5-Tornado coils (Cook Medical – Bloomington, 
United States). These fibrous coils were positioned using 
the support provided by vascular plugs (Figure 2 D). 
Additionally, a small fistula was embolised in the middle 
lobe with one MWCE-38-8-5-Nester coil (Figures 2 E 
There is marked variation in disease penetration 
and presentation; it is believed that external factors, 
such as tissue damage and wounds, are required for 
neoangiogenesis activation and telangiectasia appearance. 
The presence of pulmonary arteriovenous malformations 
allows for the passage of non-oxygenated blood into the 
left atrium, leading to cyanosis, and the occurrence of 
cerebrovascular accident is often the initial manifestation.
The present study reports the case of a patient with 
cyanosis, progressive dyspnoea, recurrent episodes of epis-
taxis, and four previous cerebrovascular accident episodes.
Case report
Male patient, 33 years old, was admitted to the 
emergency room with reduced level of consciousness, 
diversion of lip commissure to the right, right dysar-
thria, and paresthesia, with onset 24 hours earlier. At 
the consultation, he reported dyspnoea on exertion ac-
companied by cyanosis, epistaxis episodes since age 15, 
two episodes of upper gastrointestinal bleeding, and four 
ischemic cerebrovascular accidents. Since the patient had 
epilepsy, neurological monitoring was performed in order 
to investigate the hypotesis of central nervous system 
vasculitis. He reported a history of type 1 diabetes mel-
litus, hypothyroidism, and positive serology for human 
immunodeficiency virus (HIV), stage A1, with no indica-
tion of antiretrovirals. He had an uncle who had frequent 
episodes of epistaxis and intestinal bleeding. He regularly 
used NPH insulin, valproic acid, and levothyroxine.
Physical examination showed finger clubbing and 
telangiectasias on the palate. Laboratory tests showed 
hemoglobin of 17.3 g/dL. Magnetic resonance imaging 
of the brain showed multiple ischemic areas of various 
ages, consistent with acute, sub-acute, and old lesions. 
There were no cerebral arteriovenous malformations.
The cardioembolic etiology was investigated through 
echocardiography with microbubbles by transesophageal 
route, which showed passage of microbubbles in the left 
circulation, suggesting the presence of a patent foramen 
ovale or pulmonary arteriovenous malformations. Transcranial 
Doppler infused with microbubbles showed presence of 
large amounts of microbubbles at rest, accentuated during 
the Valsalva maneuver, strongly indicative of the presence 
of right-to-left shunt of high conductance.
Based on the clinical manifestations, personal and 
family history, and laboratory tests, the patient presented 
the four Curaçao criteria for the definitive diagnosis of 
hereditary hemorrhagic telangiectasia.4
The patient was then submitted to angiography 
through the right femoral artery and vein, which showed 
no coronary lesions, preserved left ventricular function, 
and presence of pulmonary arteriovenous malformations 
of high flow at the base (large fistulous sac with two 
adductor arteries, with diameters of 8 mm and 10 mm) 
and middle third of the right lung (small fistula with 
Figure 1 – In A, selective injection into the right pulmonary artery 
showing the presence of arteriovenous malformations, one of which 
was simple (arrow, upper portion) and another complex, with two 
adductor arteries (arrows, lower portion). In b, selective injection into 
the left pulmonary artery showing absence of fistulae. In c, selective 
injection into the adductor artery showing fistulous sac and involved 
vein (arrow). In D, injection into the patent foramen ovale in left cra-
nial anterior oblique view showing passage of contrast from the right 
atrium to the left atrium (arrow). RPA, right pulmonary artery; LPA, 
left pulmonary artery; LA, left atrium; RA, right atrium.
RPA
LPA
LA
RA
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and F). The procedure resulted in complete interruption 
of flow through the shunts, with immediate improve-
ment of arterial saturation in room air.
The patient was discharged in good clinical con-
dition, on clopidogrel 75 mg/day for six months, and 
acetylsalicylic acid 200 mg/day for continuous use.
After 12 months, the patient returned to the hospital 
complaining of headache, nausea, and dizziness. He was 
hospitalized with suspected meningitis, but the diagnosis 
was ruled out. A new transcranial Doppler showed the 
passage of microbubbles, suggesting the appearance of 
new arteriovenous malformation. Catheterization was 
performed and the results showed that previously oc-
cluded shunts had remained occluded; however, there 
was a new pulmonary arteriovenous malformation (small 
fistulous sac with 4-mm adductor artery) in the right lung 
(Figures 3A and 3B), which was successfully embolized 
using a MWCE-38-5-5-Stainless Steel coil (Figure 3C).
The patient has now been followed-up for 30 
months after the initial surgery, and did not have fur-
ther episodes of cerebral embolism, showing improved 
physical capacity, although with complaints of sporadic 
episodes of epistaxis.
DisCussion
The rate of development of pulmonary arteriovenous 
malformations in patients with hereditary hemorrhagic 
telangiectasia ranges between 20% to 40% per year. 
These fistulas are classified as simple, characterized 
by a small fistulous sac with one artery and one vein 
representing 80% of cases, and complex, with the pre-
sence of a more developed fistulous sac with multiple 
septa and more than one artery and vein.5 The present 
study reported on a case with the presence of simple 
fistulas in the right upper and lower lobes, as well as 
a large complex fistula in the right lower lobe, with 
two adductor arteries and a large vein, resulting in 
high right-to-left flow.
These patients are at increased risk of paradoxical 
embolism due to venous thromboembolism or thrombus 
originating from the arteriovenous malformation itself, 
which may lead to severe cerebrovascular accident or 
brain abscess. Percutaneous closure is indicated in all 
symptomatic patients (cyanosis, hemoptysis, and recur-
rent cerebrovascular accidents) and in all who have 
fistulas with arteries > 3 mm in diameter, who have a 
higher risk of paradoxical embolism.6 
There are no randomized studies demonstrating 
the best treatment option between occlusion or clinical 
Figure 2 – In A, the immediate result after patent foramen ovale occlu-
sion with Cardia prosthesis (arrow). In b, vascular plugs released in two 
adductor arteries of the large fistula in the right lung (arrows). In c, the 
immediate outcome showing residual flow after implantation of vascular 
plugs (arrows). In D, new procedure performed five days after implantation 
of additional Gianturco coils, using the plug as an anchor in the adduc-
tor arteries of the largest fistulous sac (arrows). In E and F, microfistula 
occlusion in middle lobe of the right lung with a Gianturco coil (arrow).
Figure 3 – Angiographic re-evaluation of the patient at 12 months, 
identifying adductor artery fistula in the right lung in anteroposterior 
view in A (arrow), and in right anterior oblique view in b (arrow). In c, 
the result immediately after occlusion with the Gianturco coil (arrow).
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treatment. However, there is ample evidence favouring 
occlusion regarding the decrease in the likelihood of 
cerebral embolization. Until 1977, the only available 
treatment was surgical, with morbidity and mortality of 
up to 4% to 5%; since then, percutaneous treatment 
has emerged as the preferred option, since it is safer 
and more effective.
The main complications of this procedure include 
device embolization, pleuritic pain, low fever and 
pleural effusion (10% to 35%), infection, and pulmo-
nary infarction. The contraindications are pulmonary 
hypertension (moderate and severe) or pulmonary 
infection. To prevent device displacement, devices 
should be chosen with a diameter 2-mm greater than 
the diameter of the vessel to be occluded when using 
coils, or with a diameter 20% to 30% larger than the 
vessel when employing plugs.7
In this case, there was no difficulty in effectively 
treating simple fistulas with only one coil, but the 
complex fistula had large-calibre adductor arteries, 
poorly defined septa in the fistulous sac, and a large-
calibre vein, which are predictors of high risk of coil 
embolization, with dire consequences for the systemic 
circulation. For this reason, it was chosen to use the 
AmplatzerTM Vascular plug with larger dimensions than 
that of adductor vessels, preventing the risk of emboliza-
tion. These were important for the posterior positioning 
of multiple coils due to the persistent flow through the 
fistula, after five days of follow-up, a technique suc-
cesfully used by Pereira et al.8
The concomitant presence of patent foramen 
ovale increased the chance of paradoxical throm-
boembolism, and, therefore, it was occluded with a 
25-mm Cardia prosthesis, guided by transesophageal 
echocardiography. Although the patent foramen ovale 
was small, had a short tunnel, and did not present 
interatrial septal aneurysm, the decision to occlude 
it was based on the presence of right-to-left shunt 
through the interatrial septum in a patient with mul-
tiple previous episodes of cerebrovascular accident.
The physiopathology of arteriovenous malformation 
development appears to involve not only the lack of 
inhibition of the neoangiogenesis pathway due to lack 
of activation of components of the TGF-b receptor su-
perfamily, but also tissue injury.9 Within this model, it 
is expected that new arteriovenous malformations will 
be established in the future, due to new episodes of 
injury to which biological tissues are subject. In fact, 
the recurrence rate is 3% a year.10
Despite the technical difficulty and high risk of 
occluder device embolization in complex pulmonary 
arteriovenous malformation, the initial choice of the 
vascular plug, complemented by fibrous coils, made 
the percutaneous treatment feasible and safe in this 
case. It is believed that concomitant treatment of patent 
foramen ovale was also important for an evolution free 
of embolic events at the 30-month follow-up.
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